250 related articles for article (PubMed ID: 19098892)
1. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
Llanos L; Bellot P; Zapater P; Pérez-Mateo M; Such J
Am J Gastroenterol; 2009 Jan; 104(1):257-8. PubMed ID: 19098892
[No Abstract] [Full Text] [Related]
2. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
[No Abstract] [Full Text] [Related]
3. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
4. Sorafenib-induced destructive thyroiditis.
Iavarone M; Perrino M; Viganò M; Beck-Peccoz P; Fugazzola L
Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
[No Abstract] [Full Text] [Related]
5. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
[No Abstract] [Full Text] [Related]
6. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
7. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
8. Sorafenib in advanced hepatocellular carcinoma.
Spinzi G; Paggi S
N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
[No Abstract] [Full Text] [Related]
9. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
Zhu AX; Clark JW
Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
[No Abstract] [Full Text] [Related]
10. All that glitters: sorafenib.
Abbass K; Dewani S; Markert R; Kaplon MK; Baumann MA
Intern Med; 2011; 50(7):797. PubMed ID: 21467725
[No Abstract] [Full Text] [Related]
11. Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
Rombolà F; Caravetta A; Mollo F; Spinoso A; Peluso L; Guarino R
Acta Medica (Hradec Kralove); 2011; 54(4):177-9. PubMed ID: 22283115
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
13. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.
Dogan E; Aksoy S; Arslan C; Dede DS; Altundag K
Med Oncol; 2010 Dec; 27(4):1436-7. PubMed ID: 20012235
[No Abstract] [Full Text] [Related]
14. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
[No Abstract] [Full Text] [Related]
15. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
Huang WS; Yang CH
World J Gastroenterol; 2009 Sep; 15(35):4464-6. PubMed ID: 19764104
[TBL] [Abstract][Full Text] [Related]
16. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
Coriat R; Gouya H; Mir O; Ropert S; Vignaux O; Chaussade S; Sogni P; Pol S; Blanchet B; Legmann P; Goldwasser F
PLoS One; 2011 Feb; 6(2):e16978. PubMed ID: 21340026
[TBL] [Abstract][Full Text] [Related]
17. Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients.
Mancuso A; Zavaglia C; Bai F; Puoti M; Belli LS
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1414-6. PubMed ID: 24206381
[No Abstract] [Full Text] [Related]
18. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Chan SL; Lin CC; Chiorean EG; Holcombe RF; Mulcahy MF; Carter WD; Patel K; Wilson WR; Melink TJ; Gutheil JC; Tsao CJ
Cancer Chemother Pharmacol; 2011 Aug; 68(2):539-45. PubMed ID: 21594722
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib-induced bilateral osteonecrosis of femoral heads.
Guillet M; Walter T; Scoazec JY; Vial T; Lombard-Bohas C; Dumortier J
J Clin Oncol; 2010 Jan; 28(2):e14. PubMed ID: 19884542
[No Abstract] [Full Text] [Related]
20. Drug therapy: sorafenib.
Finn RS
Hepatology; 2010 May; 51(5):1843-9. PubMed ID: 20432260
[No Abstract] [Full Text] [Related]
[Next] [New Search]